ABSTRACTS/RESEARCH REPORTS – IOWA STATE (*denotes Presenter)
Brown G, Campbell J, Jones P, Johannes C, Reddell P. Intratumoral treatment of canine high-grade mast cell tumors with tigilanol tiglate (EBC-46). Veterinary Cancer Society, October 2020. (Poster) [Virtual due to COVID-19 travel restrictions.]
Musser ML, Berger EP, Tripp CD, Clifford CA, Bergman PJ, Johannes CM. Adverse event profile of the therapeutic canine osteosarcoma vaccine, live Listeria vector. Veterinary Cancer Society, October 2020. (Oral) [Virtual due to COVID-19 travel restrictions.]
Jones P, Campbell J, De Ridder T, Johannes CM, Brown G, Morton J, Reddell P. Determinants of efficacy in a pivotal clinical study of intratumoral treatment of canine mast cell tumours with tigilanol tiglate. World Veterinary Cancer Congress, Tokyo Japan, March 2020. (Oral) [Accepted but not presented due to COVID-19 travel restrictions.]
Brown G, Campbell J, Jones P, Johannes CM, DeRidder T, Reddell P. Treatment of canine soft tissue sarcomas (STS) with intratumoural tigilanol tiglate with 40% tumour volume dosing. World Veterinary Cancer Congress, Tokyo Japan, March 2020. (Poster) [Accepted but not presented due to COVID-19 travel restrictions.]
Musser ML, Mahaffey A, Fath M, Buettner G, Wagner B, Schneider B, Seo YJ, Mochel J, Johannes CM. Evaluating high-dose intravenous vitamin C pharmacokinetics in healthy Beagle dogs. University of Iowa Hospitals & Clinics, Sarcoma Symposium, Iowa City IA, February 2020. (Oral)
Coto GM, Musser ML, Tropf M, Ward JL, Seo YJ, Mochel JP, Johannes CM. A multi-institutional, retrospective analysis of prognostic factors and treatment options for presumed or confirmed canine aortic body chemodectomas. Veterinary Cancer Society, Houston TX, October 2019. (Oral)
Campbell JE, Johannes CM, Reddell P. Durability of response to intratumoral tigilanol tiglate in canine MCT. Veterinary Cancer Society, Houston TX, October 2019. (Oral)
Wiest ML, Geller S, Pittenger ST, Burke-Schwarz C, Johannes CM*, Reddell P, Gordon V, Schmidt P, Lowden S. Controlled, randomized study of intratumoral tigilanol tiglate (EBC-46) for treatment of canine mast cell tumors. ACVIM Forum, Phoenix AZ, June 2019. (Research Report)
Musser ML, Mahaffey AL, Fath MA, Buettner GR, Wagner BA, Mochel JP, Johannes CM. In vitro and in vivo evaluation of high-dose ascorbate in dogs. ACVIM Forum, Phoenix AZ, June 2019. (Research Report)
Gettinger M, LeVine D, Viall A, Vier J, Glanemann B, Johannes C, Van Vertloo L. Retrospective evaluation of splenectomy in the treatment of canine primary immune thrombocytopenia. ACVIM Forum, Phoenix AZ, June 2019. (Oral)
Musser ML, Mahaffey AL, Fath MA, Buettner GR, Wagner BA, Mochel JP, Johannes CM*. In vitro and in vivo evaluation of high-dose ascorbate in dogs. European Society of Veterinary Oncology (ESVONC) Annual Congress, Frankfurt Germany, May 2019. (Poster)
Wiest ML, Geller S, Pittenger ST, Burke-Schwarz C, Johannes CM*, Reddell P, Gordon V, Schmidt P, Lowden S. Controlled, randomized study of intratumoral tigilanol tiglate (EBC-46) for treatment of canine mast cell tumors. European Society of Veterinary Oncology (ESVONC) Annual Congress, Frankfurt Germany, May 2019. (Oral)
Musser ML, Phillips RL, Hostetter JM, Johannes CM, Viall A. Intratumoral expression of prostaglandin EP4 receptor gene PTGER4 in multiple canine malignancies. Annual Meeting of the American College of Veterinary Pathologists and the American Society for Veterinary Clinical Pathology, Washington DC, November 2018. (Poster)
Marnin SA, Berger DJ, Viall AK, Schrunk D, Musser ML, Johannes CM. Evaluation of the potency and accuracy of compounded toceranib phosphate formulations. Veterinary Cancer Society Conference, Louisville KY, October 2018. (Oral)
Musser M, Viall A, Phillips R, Hostetter J, Johannes C. Expression of prostaglandin EP4 receptor in multiple canine malignancies. Veterinary Cancer Society Conference, Louisville KY, October 2018. (Oral)
Musser ML, Viall AK, Phillips RL, Hostetter JM, Johannes CM*. Expression of prostaglandin EP4 receptor in canine osteosarcoma. ECVIM Congress, Rotterdam, Netherlands, September 2018. (Poster)
Fowler BL, Johannes CM*, O’Connor AM, Collins D, Lustgargen J, Weishaar KM, Sullivan KE, Hume KR, Mahoney J, Vale BA, Schubert A, Ball V, Cooley-Lock KM, Curran K, Nafe LA, Gedney A, Weatherford M, LeVine DN. Ecological-level analysis of canine and feline primary lung tumors and environmental radon levels. ACVIM Forum, Seattle WA, June 2018. (Poster)
Viall AK, Phillips RL, McLeland SM, Hostetter JM, Bracha S, Musser M, Johannes CM. Intratumoral expression of serotonergic signaling system genes htr1b, htr2a, htr2b, tph1, and slc6a4 in canine osteosarcoma. ACVIM Forum, Seattle WA, June 2018. (Poster)
Musser M, Taikowski K, Johannes C, Bergman P. Retrospective evaluation of Palladia® use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas. ACVIM Forum, Seattle WA, June 2018. (Poster)
Kelly J, Padget M, Johannes CM, Masic A. Safety evaluation of multiple intravenous administrations of Immunocidin® in cats and dogs with malignancies. ACVIM Forum, Seattle WA, June 2018. (Research Report)
Musser M, Johannes C, Mochel J, Mahaffey A. Evaluating high-dose intravenous vitamin C pharmacokinetics in healthy Beagle dogs. University of Iowa Hospitals & Clinics, Sarcoma Symposium, Iowa City IA, February 2018. (Oral)
Nenninger AS, Servantes J, Hostetter S, Johannes C, Viall A. Erythrocyte cytomorphologic changes in dogs receiving the CHOP chemotherapy protocol for treatment of multicentric lymphoma. American College of Veterinary Pathologists Annual Meeting, Vancouver, Canada, December 2017. (Student Poster)
Johannes CM*, Rassnick KM, Bailey DB, Yanda NM, Regan R, Malone E, Intile JL, Kiselow M, Lucroy MD, Berger EP, Fox LE, Kamstock DA, LeBlanc CJ. Evaluation of factors associated with survival in dogs with lymphoma treated with prednisone. The Canine Lymphoma Steroid Only (CALYPSO) open-label prospective clinical trial: 69 cases (2016-2017). Veterinary Cancer Society Conference, Portland OR, October 2017. (Oral)
Fowler BL, Johannes CM, O’Connor AM, Collins D, Lustgargen J, Weishaar KM, Sullivan KE, Hume KR, Mahoney J, Vale BA, Schubert A, Ball V, Cooley-Lock KM, Curran K, Nafe LA, Gedney A, Weatherford M, LeVine DN. Ecological-level analysis of canine and feline primary lung tumors and environmental radon levels. Veterinary Cancer Society Conference, Portland OR, October 2017. (Oral)
Punt N, Johannes CM, Hackbarth L, Fox L. Current clinical management of chemotherapy-induced vomiting and inappetence in dogs. ACVIM Forum, National Harbor MD, June 2017. (Poster)
Berger E, Johannes CM, Jergens A, Allenspach K, Fox LE. Evalation of toceranib phosphate (Palladia®) in the treatment of canine gastrointestinal stromal tumors. ACVIM Forum, National Harbor MD, June 2017. (Oral)
Garraway K, Johannes CM, Allenspach K, Ackermann M, Peauroi J, Jergens A. Relationship of the mucosal microbiota to inflammation and disease activity in cats with intestinal lymphoma. ACVIM Forum, National Harbor MD, June 2017. (Oral)
Makielski K, Jeffery U, Fox L, Johannes C, Graef A, Kim J, Husbands B, Walz J, Henson M, Modiano J, LeVine D. Coated platelet potential in canine cancer patients. Veterinary Cancer Society Conference, Orlando FL, October 2016. (Poster)
Johannes CM*, Romansik EM, Lewis M, Jackson E. Tactress® clinical experience program (T-CEP): Summarizing early use of a monoclonal antibody for canine T-cell llymphoid malignancies. Veterinary Cancer Society Conference, Orlando FL, October 2016. (Poster)
Makielski K, Jeffery U, Fox L, Johannes C, Graef A, Kim J, Husbands B, Walz J, Henson M, Modiano J, LeVine D. Coated platelet potential in canine cancer patients. Platelets International Symposium, Wellesley MA, September 2016. (Poster)
Berger E, Johannes CM, Post GS, Rothchild G, Shiu KB, Wetzel S, Tripp C, Arteaga T, Crawford-Jukubiak M, Serras AR, Gillings S, Swanson C, Greene S, O’Neill K, Pressel M, Fox L. Evaluation of toceranib phosphate (Palladia®) in the treatment of feline mast cell neoplasia: 53 cases. ACVIM Forum, Denver CO, June 2016. (Poster)
Gieger TL, Nettifee-Osborne J, Hallman B, Johannes C, Clarke D, Nolan NW, Williams LE. The impact of carboplatin and toceranib phosphate on angiogenesis and survival in canine osteosarcoma. ACVIM Forum, Denver CO, June 2016. (Poster)
Johannes CM*, Snyder S, Hauck M. Expression of hedgehog signaling molecules in canine osteosarcoma. World Veterinary Cancer Congress, Foz do Iguacu, Brazil, May 2016. (Poster)
Rhodes L, Zollers B, Johannes CM*. A prospective, multi-center clinical survey evaluating inappetence in 43 dogs with cancer receiving chemotherapy. Veterinary Cancer Society Conference, Vienna VA, October 2015. (Poster)
ABSTRACTS/RESEARCH REPORTS – PRIOR TO IOWA STATE (* denotes Presenter)
Musser M, Jamadar-Shroff V, Johannes CM, Richards K, Suter S. In vitro effects of masitinib mesylate and toceranib phosphate on canine lymphoid cell lines. Veterinary Cancer Society Conference, Minneapolis MN, October 2013. (Oral)
Johannes CM*, Kavlakov B, Trettien A, Bidgood T, Meikle S. Palladia year one clinical experience: Online case entry summary. Veterinary Cancer Society Conference, San Diego CA, October 2010. (Oral)
Johannes CM*, Henry CJ, Hamilton T, Smith AN, Turnquist SE. Feline hemangiosarcoma: A retrospective of 36 cases. Veterinary Cancer Society Conference, Pacific Grove CA, October 2000. (Oral)